Share This Author
Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.
Gemfibrozil is an effective drug indicated for the treatment of severe hypertriglyceridaemia, and in certain patients with severe hypercholesterolaemia who are unresponsive to other standard therapies.
Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Diclofenac is one of the few NSAIDs of 'first choice' in the treatment of acute and chronic painful and inflammatory conditions and rarely produces gastrointestinal ulceration or other serious side effects.
Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.
Clinical experience confirms initial findings, perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
- D. Campoli-Richards, J. Monk, A. Price, P. Benfield, P. A. Todd, A. Ward
- Medicine, BiologyDrugs
- 1 April 1988
As an orally active, broad spectrum and potent antibacterial drug, ciprofloxacin offers a valuable alternative to broad spectrum parenterally administered antibacterial drugs for use in a wide range of clinical infections, including difficult infections due to multiresistant pathogens.
Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Enalapril 10 to 40 mg/day administered either once or twice daily is effective in lowering blood pressure in all grades of essential and renovascular hypertension, and shows similar efficacy to usual therapeutic dosages of hydrochlorothiazide, beta-blockers and captopril.
Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
If further study confirms long term tolerability and an impact on cardiac mortality and morbidity, then simvastatin and others of its class should offer a significant new approach to the treatment of hypercholesterolaemia.
Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
Preliminary investigations indicate that the properties of bezafibrate could contribute to an antiatherogenic effect of the drug, but further investigation is required to establish the drug's potential as chronic therapy in patients with hyperfibrinogenaemic atherosclerosis.
Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.
A favourable profile of efficacy and tolerability, and the substantial weight of clinical experience, explain the increasing acceptance of enalapril as a major antihypertensive treatment and supports its use as logical first-line therapeutic option.
Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Should the results of long term comparative studies confirm these encouraging findings, ibopamine will be a useful addition to the drugs available or as an alternative to digoxin for the treatment of congestive heart failure.
Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.
Flunarizine is useful in the prophylaxis of migraine, an effective treatment for vertigo and a worthwhile alternative as 'add-on' therapy in patients with epilepsy resistant to conventional drugs.